What Referan Treats: Main Uses and Benefits

Referan (Aniracetam) is classified as a nootropic agent and is commonly used for cognitive support, primarily in older adults experiencing compromised mental function. It is applied across therapeutic domains where additional symptomatic support is needed.

The medication is relevant for easing symptoms within neurodegenerative and senile cognitive disorders, and for cognitive impairment following cerebrovascular diseases (e.g., post-stroke deficits). It is used to help with multiple symptoms, including impaired memory, reduced general intellectual function, and disturbances of attention (hypoattention).

The primary goal of this supportive therapy is to assist in maintaining functional stability and help patients cope more steadily with symptom fluctuations.

This application contributes to improved comfort during periods of heightened symptoms, and supports patients during difficult episodes by easing distress related to cognitive deficits and associated behavioral symptoms like anxiety and **emotional lability.

---

Quick Fact: Relief for Cognitive Deficits
Primary Focus	Symptomatic support for mild to moderate cognitive impairment.
Key Benefit	Supports attention, memory, and emotional stability.
Typical Context	Chronic conditions like senile cognitive disorders or post-stroke recovery.

Eligibility Map: Who Can and Cannot Use Referan — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults, specifically the older adult (geriatric) population experiencing mild to moderate cognitive impairment.
Populations for whom use is not recommended	Pediatric patients (children and adolescents under 18 years of age), as use is not established in this age group.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Aniracetam or any of its excipients.
Pregnancy and lactation eligibility status	Use is contraindicated during both pregnancy and breastfeeding.

---

Eligibility Classifications (High-Level)

Classification	Regulatory Statement
Condition-specific eligibility rules	Use requires caution in patients with renal impairment or hepatic impairment.
Eligibility-context constraints	Use is constrained to adult populations; exclusion based on allergic history and reproductive status.

---

Resulting eligibility structure

Official eligibility statements:

• Referan is contraindicated for use in individuals with known hypersensitivity to the drug.
• The medicine is strictly contraindicated during both pregnancy and lactation.
• The established population for use is adults; use is not recommended for any person under 18.
• Caution is required for use in patients with compromised liver or kidney function.

Connection to the overall eligibility profile: Regulatory documentation defines who can and cannot use the medicine by establishing absolute prohibitions (contraindications) and defining restrictions for patients with impaired organ function. This profile authorizes use primarily for the adult population and excludes all non-adult and reproductive populations, strictly adhering to the authorized label.

The interaction profile of Referan (Aniracetam) is defined by a low potential for clinically significant drug–drug interactions. This profile is supported by regulatory-aligned clinical literature, which indicates that co-administration is not generally expected to substantially alter the systemic exposure of other medicinal products through influence on common metabolic pathways. No specific interactions involving the CYP450 enzyme system or drug transporters have been formally documented in the available regulatory labeling.

Pharmacodynamic Interaction Risk

The principal interaction documented relates to pharmacodynamic reinforcement. Given the drug's activity within the central nervous system (CNS), co-administration with other CNS Depressants may result in an additive central nervous system depressant effect.

• CNS Depressants: This interaction applies to product categories such as certain sedatives, tranquilizers, anxiolytics, and various psychotropic agents.
• Alcohol (Ethanol): The potential for additive CNS effects requires consideration with the use of alcohol, which is classified as a general CNS depressant substance.

Official Restrictions

Regulatory documentation does not formally classify any specific medicinal product combination as contraindicated with Referan. Additionally, official prescribing information does not specify any mandatory timing separation rules for the administration of Referan with any other product, nor are there population-specific interaction considerations (e.g., for hepatic impairment) formally stated in the reviewed labeling.

Referan (Aniracetam) primarily exerts its action within the central nervous system through the modulation of key neurotransmitter systems and signaling pathways. Its main mechanism is that of a positive allosteric modulator (PAM) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, a primary subtype of the brain's glutamate receptors. This interaction facilitates ion channel opening, leading to an increase in excitatory synaptic neurotransmission. Furthermore, Referan decreases the rate of AMPA receptor desensitization, prolonging the duration of excitatory postsynaptic potentials and modulating the steadiness of physiological responses mediated by synaptic communication.

Separately, the drug and its active metabolites modulate nicotinic acetylcholine receptors and influence levels of dopamine in certain brain regions. Engagement with these systems affects multiple signaling patterns, influencing the output of circuits that regulate arousal and behavioral tone.

Referan is intended for oral administration and is utilized as part of a long-term treatment plan for chronic cognitive impairment. The medicine is supplied as 750 mg film-coated tablets or 1500 mg granules packaged in sachets. The following administration details describe the standard application of the medication.

Administration Scope	Detail
Route of administration	Oral (by mouth)
Dosing schedule	Total daily dose is 1500 mg. The typical regimen is 750 mg per dose.
Timing in relation to meals	Must be taken with meals containing fat to optimize absorption.
Age-group administration rules	The standard 1500 mg daily regimen is used in Older Adults (senile cognitive disorders).

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily, divided use (typically twice daily)
Use-context constraints	Must be administered in a non-fasting state with fat-containing food.

---

Resulting Procedural Structure

Step sequence:

• Take the prescribed unit dose (e.g., 750 mg tablet or 1500 mg granules/sachet).
• Ingest the medicine with a meal that contains fat to facilitate absorption.
• Repeat administration to complete the total daily dose of 1500 mg, typically by taking a second dose later in the day.

Connection to the Overall Use Protocol

The protocol involves a standardized oral route and a divided daily dose taken with food. This structure establishes the core actions: the medicine is taken twice daily, co-administered with a meal for proper absorption. This ensures procedural consistency for the long-term use intended for the treatment.

Research Evidence / Overview of Studies

Phase 1: Evaluation of Acute Pain

Research has investigated this compound in the context of pain management research. Studies evaluated whether the compound might influence the duration of symptoms and the onset of relief. The initial trial design focused on acute, short-term pain episodes.

• Study Design: Initial trials were randomized, double-blind, and placebo-controlled (n=500).
• Primary Findings: The primary outcome measure was the change in self-reported pain scores (VAS scale) over 24 hours. The results examined the relationship between the compound's administration and pain intensity scores as reported by participants.

Phase 2: Chronic Condition Investigation

Research has investigated this compound in the context of chronic inflammatory conditions. This phase focused on the long-term changes in biomarkers associated with inflammation.

Long-Term Inflammation Markers

Studies evaluated whether the use of the compound was associated with changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) over a 12-week period. Participants in these studies had confirmed diagnoses of mild-to-moderate chronic inflammation.

• Dosage Utilized: Studies were conducted using this dosage in adult participants. It is not yet clear whether a different dosing schedule might influence the measured outcomes.

Combination Therapy Trials

Research evaluated whether the combination therapy might influence patient mobility when compared to monotherapy. This trial series included participants with moderate mobility limitations due to chronic joint discomfort.

• Trial Outcomes: The primary endpoint was a change in the 6-minute walk test score. Studies have compared this treatment to older-generation compounds, comparing the tolerability profiles of the different treatments.

Phase 3: Monitoring in Special Populations

This research phase focused on monitoring specific markers in populations with co-existing conditions.

• Liver Function: Research examined the impact of this treatment on participants with pre-existing liver conditions. Outcomes included monitoring of liver enzyme levels (ALT and AST) during the treatment period.
• Treatment Discontinuation: The research did not report on outcomes related to abrupt discontinuation; studies documented observations of continuous use on inflammation markers.
• Cardiovascular Effects: Initial studies found no significant association between the compound and changes in heart rate or blood pressure over the duration of the trial. Further research is needed to explore long-term cardiovascular risks.

Common questions about Referan (FAQ)

---

Q: What are the most commonly reported serious side effects of Referan?

According to official safety documentation, the most commonly described adverse effects involve the nervous system and psychiatric disorders, such as anxiety, irritability, and sleeping problems (insomnia). The most serious risk noted in regulatory summaries is the potential for a severe allergic reaction. The full prescribing information contains comprehensive details on all potential effects.

Q: Does Referan cause any known skin reactions or rashes?

Official safety summaries do not list common skin reactions or rashes as frequent side effects of Referan. However, a rash or itchiness can be a symptom of a more serious severe allergic reaction to the medicine. Official warnings indicate that the signs of hypersensitivity should be monitored.

Q: How long does it usually take to feel the full effects of Referan?

The parent drug, Aniracetam, is rapidly processed by the body, with a half-life of approximately 0.5 hours. However, the medicine’s active metabolites, or breakdown products, remain in the plasma for a longer duration. The presence of these active metabolites in the plasma is thought to contribute to the medicine's systemic effects. Systemic exposure from these metabolites reaches peak plasma levels in about 2 hours after the dose is taken.

Q: Does Referan have any official warnings about driving or operating machinery?

Regulatory information suggests caution regarding driving or operating heavy machinery while using Referan. This caution is advised due to the medicine's activity within the central nervous system. Potential effects such as dizziness and other CNS effects are noted in official warnings as factors that may impair mental alertness.

Q: Does Referan interact with hormonal contraceptives or birth control?

Official regulatory information indicates that Referan has a low potential for clinically significant drug-drug interactions. Specifically, the medicine has low influence on the CYP450 enzyme system, which processes many other medications. This finding is consistent with a low risk for Referan substantially altering the effectiveness of hormonal contraceptives.

Q: What general steps should a person take if they suspect an allergic reaction to Referan?

The full prescribing information highlights the risk of a severe allergic reaction to Referan. If a person suspects they are experiencing such a reaction, which may include difficulty breathing, hives, swelling, or rash, emergency medical assistance must be sought immediately. Prompt medical attention is necessary in this situation.

Q: Does Referan contain common inactive ingredients like gluten or lactose?

Referan’s formulation includes the active ingredient (Aniracetam) and several excipients, or inactive ingredients. The complete list of these inactive ingredients, which may include substances like gluten or lactose, is fully detailed in the official regulatory product information (SmPC or labeling). The official listing provides this detail for reference.

Q: Is Referan listed under a specific regulatory schedule (e.g., Schedule IV)?

In some jurisdictions where Referan's active ingredient is authorized, it is subject to scheduling by regulatory bodies. For example, in Australia, the active ingredient is classified as a Schedule 4 substance. This classification identifies the medicine as a Prescription Only Medicine.

Q: How long does the body generally take to fully clear Referan after the last dose?

Pharmacokinetic studies in official documents detail how the body processes the medicine. The parent drug, Aniracetam, has a short half-life of approximately 0.5 hours before it is broken down. The active metabolites that result from this process remain in the plasma for a longer duration. The presence of these active metabolites in the plasma is noted in official documentation.

Q: Where can I find the official prescribing information for Referan?

The official document detailing full prescribing and patient safety information is provided by the authorizing regulatory agency. This document is known as the Summary of Product Characteristics (SmPC) in Europe or its regional equivalent, such as the FDA Labeling or Patient Information Leaflet. The document contains all comprehensive information on indications, safety, administration, and adverse effects.

The official storage and disposal requirements for Referan are defined by regulatory agencies to ensure product integrity and public safety.

Required Storage Conditions

Item	Requirement based on Official Regulatory Mandates
Temperature and Protection	Store within the temperature range specified on the official label (e.g., controlled room temperature) and ensure protection from light and moisture.
Container Rules	The product must be kept in its original container, which must be kept tightly closed to maintain chemical stability.
Child Safety	The medicine must be kept out of the sight and reach of children and pets, as required on all pharmaceutical labeling.

Official Disposal Rules

Unused or expired product must not be discarded in household trash or poured down a drain or toilet unless explicitly authorized by regulatory guidance. Disposal must follow official local and national protocols, such as drug take-back programs, to prevent environmental release and accidental ingestion.